3one4 Capital

Bengaluru produces a particular kind of investor: one who has watched Indian consumer behavior shift through three platform cycles and still believes the most interesting bets are the ones that compress middle-class friction into software. 3one4 Capital sits in that lineage. Founded in 2016 by brothers Pranav Pai and Siddarth Pai, the firm has built a reputation for backing companies that solve operational problems Indian institutions have failed to solve themselves, and for staying patient through the long arc between seed and meaningful revenue. With roughly USD 520 million across vehicles and a portfolio that now extends across consumer, fintech, SaaS and digital health, 3one4 is positioned as one of the country’s few truly thesis-led early-stage funds, willing to underwrite category creation in a market where most capital still chases category extension.

The firm’s investment thesis is built around what it calls generational innovation engines: companies that benefit from durable structural shifts in the Indian economy rather than from a single product cycle. In healthcare specifically, the team views India’s surgical, diagnostic and chronic-care infrastructure as fundamentally underbuilt relative to demand, and digital health businesses as the most realistic mechanism to close that gap at population scale. The fund prefers founders who treat distribution, regulation and capital efficiency as core product surfaces rather than later-stage problems. It is also notably comfortable with longer feedback loops; healthcare investments are evaluated against ten-year compounding curves, not next-round markups. AI is treated as an enabling layer rather than a category, and the firm has been explicit that it will not back companies whose only differentiation is model access. What it wants instead are operating systems for entire workflows, where AI sits inside a defensible data and distribution moat.

The portfolio reflects this discipline. HexaHealth, the Gurugram-based tech-enabled surgical care platform, is the clearest healthcare expression of the thesis: 3one4 led the company’s Series A alongside Orios Venture Partners, backing a team building patient navigation, hospital partnerships and AI-personalized journeys across more than 350 facilities including Fortis, Apollo, Max and Manipal. The firm’s broader portfolio has been reported to include other healthtech bets in primary care and chronic disease management, and the wider book extends across consumer fintech and B2B software. For founders, the relevant signal is that 3one4 is comfortable being the institutional anchor on a Series A in a category where most Indian generalists are still avoiding clinical workflows, and that it has shown willingness to follow on through subsequent rounds when execution justifies it.

On stage and check size, 3one4 operates across pre-seed, seed and Series A, with selective participation in later rounds out of its growth and opportunity vehicles. Initial checks at seed typically range from a few hundred thousand to several million dollars, scaling to higher entries at Series A where the fund is willing to lead. The firm explicitly publishes that it can be either the first institutional check or a co-lead with a strategic partner, and it is one of the few Indian funds that will write conviction checks before clinical validation in healthcare provided the founder has credible operating context. Reserve ratios are meaningful, and follow-on participation through the growth vehicle gives founders a single relationship across multiple rounds.

Decision-making is anchored by Pranav Pai, who serves as Founding Partner and Chief Investment Officer, and Siddarth Pai, also a Founding Partner. The firm has built a roughly ten-person investment team over the past decade, and partners take individual ownership of deals rather than relying on a committee-driven sponsor model. Healthcare deals in particular tend to run through partners with operating exposure to Indian provider networks, and the diligence process is unusually willing to spend time with hospital CIOs, clinicians and regulators before a term sheet rather than after.

The most reliable approach to 3one4 is through founder introductions. The firm is highly active in the Indian operator community, and warm referrals from existing portfolio CEOs carry meaningful weight. LinkedIn outreach to either Pranav or Siddarth Pai is read but rarely converted; better is an introduction from an institutional LP, a follow-on co-investor like Chiratae or Orios, or an angel who has already syndicated with the firm. Founders should expect a methodical process and should arrive with a sharpened answer on the unit economics of their first 1,000 patients or customers, not just total addressable market.

What founders should know is that 3one4 underwrites for ten-year horizons in a market that often demands three-year exits, and the firm tends to prefer companies willing to grow into their TAM rather than buy it. The team is candid about wanting governance discipline early, and operators who view monthly reporting and board hygiene as friction may struggle. For digital health founders specifically, 3one4 is one of the few capital sources in India that combines clinical patience with consumer-software rigor, and that combination is what makes the firm worth the longer process.